Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Suspended 1Not yet recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Specimen Handling 31Magnetic Resonance Spectroscopy 19Biopsy 16Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Bevacizumab 7Azacitidine 7pembrolizumab 6Radiotherapy 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Surgical Procedures, Operative 5Rituximab 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × taletrectinib × Clear all
NCT06214793 2025-05-01

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Case Comprehensive Cancer Center

Phase 2 Suspended
61 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡